The molecular targeted therapy was statistically associated with better clinical survival (HR 0.271; 95% CI; 0.074-0.992, p =0.049), and WHO functional classification III or IV was associated with poor survival (HR 3.379; 95% CI; 0.874-13.069, p =0.078) with borderline significance.
← all excerpts
Functional class and targeted therapy are related to the survival in patients with pulmonary arterial hypertension.
1
—
—